Foundation Healthcare Holdings (SGX:FHH) Research & Development: S$ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:FHH Foundation Healthcare Holdings Ltd SGX:FHH
12 GF Score
Price S$0.77
! 1 Warning Sign
View Full Analysis

What is Foundation Healthcare Holdings Research & Development?

Foundation Healthcare Holdings SGX:FHH -4.35% 12 Research & Development is S$ Mil as of Dec. 2025. GuruFocus rates SGX:FHH with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Foundation Healthcare Holdings's Research & Development for the three months ended in Dec. 2025 was S$0.0 Mil. Foundation Healthcare Holdings does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2025.

Foundation Healthcare Holdings  (SGX:FHH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Foundation Healthcare Holdings Research & Development Related Terms

Foundation Healthcare Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Foundation Healthcare Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foundation Healthcare Holdings Research & Development Chart

Foundation Healthcare Holdings Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00

Foundation Healthcare Holdings Quarterly Data
Dec23 Dec24 Dec25
Research & Development 0.00 0.00 0.00
SGX:FHH
12GF Score
Foundation Healthcare Holdings Ltd SGX:FHH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foundation Healthcare Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of S$ Mil mean?
Foundation Healthcare Holdings (SGX:FHH) has a Research & Development of S$ Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Foundation Healthcare Holdings and its competitors.
Is Foundation Healthcare Holdings' Research & Development too high?
Foundation Healthcare Holdings' current Research & Development is S$ Mil. Overall, Foundation Healthcare Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Foundation Healthcare Holdings' Research & Development compare to HCA and THC?
Foundation Healthcare Holdings' Research & Development of S$ Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Foundation Healthcare Holdings and its competitors. Foundation Healthcare Holdings's current Research & Development is S$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foundation Healthcare Holdings stock overvalued right now?
Foundation Healthcare Holdings (SGX:FHH) has a current Research & Development of S$ Mil. The current Research & Development is S$ Mil. Foundation Healthcare Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Foundation Healthcare Holdings (SGX:FHH), the current Research & Development is S$ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Foundation Healthcare Holdings Business Description

Address 238A Thomson Road, No. 13-10 Novena Square, Singapore, SGP, 307684
Foundation Healthcare Holdings Ltd is an integrated private healthcare platform that connects medical specialists, healthcare providers, payors, patients and facilities across the healthcare ecosystem in Singapore. The company has two reportable business segments: (i) medical specialists and (ii) others, which comprise the medical centres and technology platform. The majority of revenue is derived from the Medical Specialists segment, which generates revenue from consultation fees, medical procedures (such as surgeries) performed by the medical specialists in medical facilities, and sales of drugs and consumables. Geographically, the company's operations are solely in Singapore.
12GF Score

Get the complete analysis for SGX:FHH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.77
Price